ClinicalTrials.gg
Not yet recruitingNCT07850154Updated Sep 30, 2026

Impact of Robotic Versus Endoscopic Surgery on Nipple Nerve Function Following Nipple-Sparing Mastectomy for Breast Cancer

An interventional study of Robotic-assisted nipple-sparing mastectomy and Endoscopic-assisted nipple-sparing mastectomy in Breast Neoplasms, sponsored by Guangzhou Women and Children's Medical Center. Not yet recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Guangzhou Women and Children's Medical Center · Not applicable, Interventional, and Treatment

How we know

Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
374
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,936 studies in Breast Neoplasms with a site in China — 871 open to participants now, 1,068 under way, 211 of them phase 3. Breast Neoplasms · China.

Planned enrollment
320th of 1,525
374 · median 120
Started
2026
with 191 others
No phase
328 of 1,936
171 open now
Primary completion
2027-10
later than 734 of 1,067 live
Registered
1,916th of 1,936
by date

Among the 1,936 studies in Breast Neoplasms with a site in China, this one is the 320th largest by planned enrollment of the 1,525 interventional ones that give a count, is one of 192 that started in 2026, is one of 328 with no phase, reaches primary completion later than 734 of the 1,067 other live ones, and was the 1,916th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

871 of the 1,936 studies in Breast Neoplasms with a site in China are open now. Recruiting first, the newest first:

866 more — sign in →

All 871 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,936 studies in Breast Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, prospective, randomized parallel controlled two arm clinical trial, designed to systematically evaluate impact of robotic versus endoscopic surgery on breast nerve function in patients undergoing nipple sparing mastectomy for breast cancer. The study will comprehensively assess the neurological functional outcomes, oncological safety, quality of life and sexual health, perioperative efficacy, surgical complications, and health economic value of the two minimally invasive approaches.

This study has been approved by the Institutional Review Board of the Affiliated Women and Children's Medical Center of Guangzhou Medical University. Written informed consent will be obtained from all eligible participants prior to enrollment. All patient data will be anonymized and kept strictly confidential. Statistical analyses will be performed using SPSS 27.0 software, with a P value \< 0.05 set as the threshold for statistical significance.

03

Conditions studied

  • Breast Neoplasms

Browse trials for

Keywords

  • Breast cancer
  • Nipple-sparing mastectomy
  • Robot-assisted surgery
  • Endoscopic surgery
  • Sensation
  • Erection
  • Quality of Life
  • Sexual well-being
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ductal carcinoma in situ (DCIS), or invasive breast cancer with clinical stage T1-T3, N0-N1 and no distant ;
  2. Breast size ≤ cup C, without significant breast ptosis;
  3. Patients with high aesthetic requirements who elect single-incision robotic or endoscopic-assisted nipple-sparing mastectomy;
  4. Patients eligible for prophylactic mastectomy;
  5. Patients understand the study protocol and sign the written form.

Exclusion criteria

Exclusion Criteria:

  1. Tumor invasion of the nipple-areola complex, skin, or chest wall;
  2. Inflammatory breast cancer;
  3. Patients with poor general condition who are unable to tolerate surgery.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
374 participants (estimated)

Study arms

  • Experimental
    Robotic-assisted nipple-sparing mastectomy group

    Patients undergo robotic-assisted nipple-sparing mastectomy for breast cancer.

    Procedure: Robotic-assisted nipple-sparing mastectomy

  • Experimental
    Endoscopic-assisted nipple-sparing subcutaneous mastectomy group

    Patients undergo endoscopic-assisted nipple-sparing mastectomy for breast cancer.

    Procedure: Endoscopic-assisted nipple-sparing mastectomy

Interventions

  • ProcedureRobotic-assisted nipple-sparing mastectomy

    Robotic-assisted nipple-sparing mastectomy for breast cancer.

  • ProcedureEndoscopic-assisted nipple-sparing mastectomy

    Endoscopic-assisted nipple-sparing mastectomy for breast cancer.

06

What researchers measure

Primary outcomes

  1. Tactile pressure sensation of the nipple-areola complex at 6 months postoperatively

    Tactile pressure sensation will be measured using Semmes-Weinstein monofilaments. The examiner will apply the device to the nipple-areola complex, using filaments of incrementally increasing force (0.07 g, 0.4 g, 2.0 g, 4.0 g, 300 g), and record the lightest filament detectable by the patient.

    Time frame: 12 months postoperatively

  2. Positive surgical margin rate

    Time frame: Intraoperative / postoperative (2 weeks after surgery)

Secondary outcomes

  1. Tactile pressure sensation of the nipple-areola complex and breast skin at multiple postoperative time points

    Tactile pressure sensation will be measured using Semmes-Weinstein monofilaments. The examiner will apply the device to the nipple-areola complex and predefined quadrants of the surrounding breast skin, using filaments of incrementally increasing force (0.07 g, 0.4 g, 2.0 g, 4.0 g, 300 g), and record the lightest filament detectable by the patient.

    Time frame: Baseline, 1 week, 2 weeks, 1 month, 3 months, 6 months, 12 months, 18 months and 24 months postoperatively

  2. Temperature sensation of the nipple-areola complex and breast skin

    Temperature sensation will be assessed at the nipple-areola complex and predefined quadrants of the breast skin. Cold sensation is tested with an ice hammer, and warm sensation is tested using the heating mode of a massage device.

    Time frame: Baseline, 1 week, 2 weeks, 1 month, 3 months, 6 months, 12 months, 18 months and 24 months postoperatively

  3. Erection function of the nipple-areola complex

    Nipple erection function will be evaluated by stimulation of the nipple-areola complex using the vibration mode of a massage device.

    Time frame: Baseline, 1 week, 2 weeks, 1 month, 3 months, 6 months, 12 months, 18 months and 24 months postoperatively

  4. Patient-reported outcomes

    Patient-reported breast-specific sensory function, quality of life and sexual well-being will be assessed using the BREAST-Q™ Sensation Module (Pre- and Postoperative) Version 2.0 and BREAST-Q™ Breast Cancer Core Scale (Pre- and Postoperative) Version 2.0 (Sexual Well-being subscale). All subscales yield Rasch-transformed scores ranging from 0 (worst outcome) to 100 (best outcome): higher scores represent better breast sensory function, fewer breast symptoms, less negative quality-of-life impact from breast sensation alteration, and superior sexual well-being, respectively.

    Time frame: Baseline, 1 week, 2 weeks, 1 month, 3 months, 6 months, 12 months, 18 months and 24 months postoperatively

  5. Disease-free survival (DFS)

    Disease-free survival (DFS), defined as the time from surgery to the first occurrence of recurrence, metastasis, or death. DFS will be compared between the two study groups.

    Time frame: Following surgery up to 3 years

  6. Overall survival (OS)

    Overall survival (OS), defined as the time from surgery to death from any cause. OS will be compared between the two study groups.

    Time frame: Following surgery up to 3 years

  7. Recurrence and Metastasis Events

    The incidence of axillary recurrence, locoregional recurrence, and distant metastasis is compared between the two groups, with all events confirmed by histopathological or radiological evidence.

    Time frame: Following surgery up to 3 years

  8. Postoperative Complications

    The incidence of postoperative complications, including but not limited to: nipple-areola complex necrosis, infection, seroma, hematoma, is compared between the two groups.

    Time frame: Within 30 days post-surgery and at long-term follow-up assessments

  9. Cost-Utility Analysis

    A cost-utility analysis will be performed to compare the two groups. The incremental cost-utility ratio (ICUR) will be calculated to evaluate the cost-utility of the two surgical strategies.

    Time frame: Following surgery up to 3 years

  10. Operative Time

    Operative time (minutes) is compared between the two groups.

    Time frame: During surgery, recorded in the operative note

  11. Axillary operation

    Record the axillary surgical procedure of the two groups (None/Sentinel lymph node dissection/Axillary lymph node dissection)

    Time frame: During surgery, recorded in the operative note

  12. Intraoperative Blood Loss

    Intraoperative Blood Loss(mL) is compared between the robotic-assisted and endoscopic-assisted axillary lymph node dissection groups.

    Time frame: During surgery, recorded in the operative note

  13. Postoperative Recovery Parameters

    Length of postoperative hospital stay (days) and duration of postoperative drainage (days) are compared between the robotic-assisted and endoscopic-assisted groups.

    Time frame: During index hospitalization and within 30 days post-surgery

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared due to the prospective design of this study and concerns regarding patient privacy and confidentiality. The data are collected in accordance with the study protocol under the approval of the ethics committee, with written informed consent obtained from all enrolled participants, and the original consent forms do not include provisions for data sharing with external researchers. Therefore, IPD sharing is not planned. However, summarized data and analytical codes may be available from the corresponding author upon reasonable request, subject to institutional and ethical approval.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 12 months is below that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2026
First posted
Sep 30, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Oct 1, 2027
CompletionEst.
Oct 1, 2031
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07850154
Lead sponsor
Guangzhou Women and Children's Medical Center
Responsible party
haiyanli (Chief Physician, Department of Breast Surgery, Guangzhou Women and Children's Medical Center) — Principal investigator
First posted
Sep 30, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Oct 1, 2027 (estimated)
Completion
Oct 1, 2031 (estimated)
Last update
Sep 30, 2026

Study contacts

Haiyan Li
Contact
lihaiyan@gwcmc.org
+8615813340604

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion